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Correction to: Scientific Reports https://doi.org/10.1038/s41598-017-02279-x, published online 17 May 2017
The Article contains errors.
Reference 12 is cited to support a statement that YB-1 is up-regulated in different cancers, and that YB-1 overexpression is linked to adverse clinical outcomes. However, this reference reports that the results are dependent on the antibody against YB-1. As such the authors do not think its citation in the original text is appropriate and wish to remove it.
As a result, in the Introduction, "Given the "oncogenic" nature of these functions, it is not unexpected that up-regulation of YB-1 has been reported in virtually all human cancer types, including epithelial and mesenchymal solid cancers 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 as well as haematological diseases like lymphoma and leukaemia 17, 18 . YB-1 overexpression has been linked to adverse clinical outcome and poor therapy response in most of them 7, 8, 9, 10, 11, 12, 14, 15, 17, 18 , making it a promising prognostic biomarker in cancer. " should read: "Given the "oncogenic" nature of these functions, it is not unexpected that up-regulation of YB-1 has been reported in virtually all human cancer types, including epithelial and mesenchymal solid cancers 7, 8, 9, 10, 11, 13, 14, 15, 16 as well as haematological diseases like lymphoma and leukaemia 17, 18 . YB-1 overexpression has been linked to adverse clinical outcome and poor therapy response in most of them 7, 8, 9, 10, 11, 14, 15, 17, 18 , making it a promising prognostic biomarker in cancer. " Additionally, the following sentence citing this reference should be included in the Materials and Methods section, under the subheading 'Immunochemistry':
